Iyuzeh®
Latanoprost 0.005% · preservative-free ophthalmic solution
Antiglaucoma
Approved uses
Open-angle glaucoma or ocular hypertension
One drop in the affected eye(s) once daily in the evening; not to exceed once daily.
IOP starts falling 3 to 4 hours after instillation, peaks at 8 to 12 hours, and stays reduced 24 hours.
OFF-LABELNot in the FDA label for this product
Chronic angle-closure glaucoma
One drop once daily in the evening, the same regimen as the labeled indication (dosed at 9 PM in the trial).
RCT · n=275 · preserved drug
Randomized, double-masked, 12-week multicenter trial in chronic angle-closure glaucoma (latanoprost n=137, timolol n=138): mean change in daily IOP was -8.2 mmHg vs -5.2 mmHg on timolol BID, difference -3.0 mmHg (95% CI -4.0 to -2.1), P<0.001, favoring latanoprost. Studied with preserved latanoprost, not with this preservative-free formulation.
Pediatric glaucoma
Latanoprost 0.005%, one drop once daily at 8 PM (dose used in the trial, ages 0 to 18 years).
RCT · n=137 · not superior
Phase 3, randomized, double-masked, 12-week multicenter trial, 137 treated: mean IOP reduction at week 12 was 7.2 mmHg vs 5.7 mmHg on timolol, difference 1.5 mmHg (95% CI -0.8 to 3.7, P=0.21), meeting the noninferiority margin without showing superiority; responders 60% vs 52% (P=0.33), both well tolerated over 3 months. Studied with preserved latanoprost; this label states pediatric safety and effectiveness are not established.
Contraindications
Known hypersensitivity to latanoprost or any other ingredient in this product.
0.005% (50 mcg/mL) preservative-free ophthalmic solution, 0.2 mL single-dose containers, carton of 30, 5 containers per foil pouch
Prostaglandin F2alpha analogue supplied as an isopropyl ester prodrug that corneal esterases hydrolyze to the active acid. It is believed to reduce IOP by increasing the outflow of aqueous humor, and studies in animals and man suggest that the main mechanism is increased uveoscleral outflow. Onset is about 3 to 4 hours after instillation, maximum effect 8 to 12 hours, and IOP reduction persists at least 24 hours. A review of topical prostaglandin analogs reports that one well-studied mechanism for enhanced outflow is the regulation of matrix metalloproteinases and remodeling of extracellular matrix, and that another proposed mechanism is widening of the connective tissue-filled spaces.
Warnings & Precautions
- Iris pigmentation: Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris; pigmentation is expected to increase as long as latanoprost is administered. Iris pigmentation is likely to be permanent after discontinuation, and the long-term effects of increased pigmentation are not known. Inform patients of the possibility of increased pigmentation. Patients who develop noticeably increased iris pigmentation can continue treatment but should be examined regularly.
- Periorbital and lash changes: Eyelid skin darkening plus increased eyelash length, thickness, pigmentation, number, and misdirected growth in the treated eye; reported reversible in some patients after discontinuation.
- Intraocular inflammation: Caution with a history of iritis or uveitis, and generally not for use with active intraocular inflammation, which may be exacerbated.
- Macular edema: Macular edema including cystoid macular edema has been reported; caution in aphakia, in pseudophakia with a torn posterior lens capsule, and with other known risk factors.
- Herpetic keratitis: Reactivation of herpes simplex keratitis has been reported; caution with a history of it and avoid in active herpes simplex keratitis, which may be exacerbated.
- Paradoxical elevations in IOP: The dosage should not exceed once daily, and the combined use of two or more prostaglandins, or prostaglandin analogs including IYUZEH, is not recommended. Administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
- Precipitation: In vitro, precipitation occurs when eye drops containing thimerosal are mixed with the preserved 0.005% latanoprost reference product; separate concurrent topical drops by at least 5 minutes.
- Contact lens use: Contact lenses should be removed prior to the administration of IYUZEH and may be reinserted 15 minutes after administration.
Common Side Effects
In clinical trials (n=378), ocular adverse reactions reported by at least 1% of subjects were conjunctival hyperemia (34%), eye irritation (19%), eye pruritus (15%), abnormal sensation in eye (14%), foreign body sensation in eyes (12%), vision blurred (7%), lacrimation increased (5%), and photophobia (3%). Iris pigmentation changes, eyelid skin darkening, and eyelash changes have been reported. Postmarketing reactions, for which it is not always possible to reliably estimate frequency, include intraocular inflammation (iritis/uveitis), macular edema including cystoid macular edema, herpes keratitis, keratitis, corneal edema and erosions, deepening of the eyelid sulcus, trichiasis, iris cyst, pseudopemphigoid of the ocular conjunctiva, asthma and exacerbation of asthma, dyspnea, headache, dizziness, angina, palpitations, chest pain, nausea, vomiting, and toxic epidermal necrolysis.
Pregnancy: No adequate and well-controlled studies in pregnant women. IV latanoprost given to pregnant rabbits and rats through organogenesis produced malformations, embryofetal lethality, and abortion at 1.3 to 324 times the maximum recommended human ophthalmic dose.
Lactation: It is not known whether this drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when IYUZEH is administered to a nursing woman. Weigh the benefits of breastfeeding against maternal need and potential effects on the breastfed infant.
Safety and effectiveness not established in pediatric patients.